Regueiro, Miguel
Delbecque, Laure
Hunter, Theresa http://orcid.org/0000-0001-8412-9175
Stassek, Larissa
Harding, Gale
Lewis, James
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 6 January 2023
Accepted: 29 June 2023
First Online: 20 July 2023
Declarations
:
: This study was conducted in compliance with good clinical practice guidelines, including International Conference on Harmonization guidelines. In addition, all applicable local laws and regulatory requirements were adhered to throughout the study. Before participants were recruited, all study documents were submitted and approved by the Advarra IRB; the approval number is Pro00046399.
: All patients and clinicians who participated in this study provided consent for the publication of their information and responses.
: LD and THG are employees and shareholders of Eli Lilly and Company, which provided financial support for this study. LS and GH are employees of Evidera, which performed this research. JDL consulted or served on an advisory board for Eli Lilly and company, Samsung Bioepis, UCB, Bristol-Myers Squibb, Nestle Health Science, Merck, Celgene, Janssen Pharmaceuticals, Bridge Biotherapeutics, Entasis Therapeutics, AbbVie, Pfizer, Gilead, Arena Pharmaceuticals, Protagonist Therapeutics, Amgen, and Scipher Medicine. He has received research funding from Nestle Health Science, Takeda, Janssen Pharmaceuticals, and AbbVie. He has performed legal work on behalf of generic manufacturers of ranitidine, including L. Perrigo Company; Glenmark Pharmaceuticals, Inc.; Amneal Pharmaceuticals, LLC; Aurobindo Pharma USA, Inc.; Dr. Reddy’s Laboratories, Inc.; Novitium Pharma; Ranbaxy, Inc.; Sun Pharmaceutical Industries, Inc.; Strides Pharma, Inc.; and Wockhardt USA, LLC. He owns stock in Dark Canyon Labs.